Arbutus

Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna

Retrieved on: 
Thursday, April 4, 2024
Plaintiff, Patent, District court, COVID-19, CFBV, Arbutus, Sale, Messenger, Moderna, Virology, Interim, Court, LNP

8,058,069, 8,492,359, 8,822,668, 9,364,435, 9,504,651, and 11,141,378 in the manufacture and sale of MRNA-1273, Moderna’s vaccine for COVID-19.

Key Points: 
  • 8,058,069, 8,492,359, 8,822,668, 9,364,435, 9,504,651, and 11,141,378 in the manufacture and sale of MRNA-1273, Moderna’s vaccine for COVID-19.
  • The following summarizes the Court’s Opinion:
    The Court agreed with Plaintiffs’ position that the claimed molar percentage (mol.
  • %) ranges can be met by any particle and is not limited to “finished” particles that are not subjected to further process steps.
  • “We are pleased with how the Court construed the disputed claim terms,” said Michael J. McElhaugh, Interim President and Chief Executive Officer of Arbutus Biopharma.

Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments

Retrieved on: 
Wednesday, March 20, 2024
MERS, Patient, Ethics, Epidemic, NUC, Group 3, Clinical trial, Liver, Depreciation, Vaccine, Hepatitis, PD-1, Research, Coalition, Arbutus, Hepatology, Coeliac disease, Nivolumab, Safety, Immune system, CHB, Prostate cancer, CEPI, AASLD, University, Șaeș, Cancer, HBV, Conference, AstraZeneca, Autoimmunity, Infection, Human papillomavirus infection, Oxford University Innovation, SNAP, HPV, APOLLO, Pharmaceutical industry

Barinthus Bio is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer.

Key Points: 
  • Barinthus Bio is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer.
  • We presented the final data in June 2023 at the European Association for the Study of the Liver Congress 2023 – The International Liver CongressTM.
  • We presented this data during an oral presentation at the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2023.
  • In November 2023, we announced the company’s renaming as Barinthus Biotherapeutics plc to represent the evolution and expansion of its focus beyond vaccines.

Arbutus to Participate in Two Upcoming Investor Conferences

Retrieved on: 
Friday, March 8, 2024
Arbutus, Barclays, Virology, Webcast, CFBV, Conference

WARMINSTER, Pa., March 08, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Arbutus management team will participate in and host one-on-one meetings at the following two upcoming investor conferences which are being held in Miami, FL:

Key Points: 
  • WARMINSTER, Pa., March 08, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Arbutus management team will participate in and host one-on-one meetings at the following two upcoming investor conferences which are being held in Miami, FL:
    Barclays 26th Annual Global Healthcare Conference: Formal Presentation on March 12, 2024 at 2:05 pm ET
    Jefferies Biotech on the Bay Summit: March 13, 2024
    To access the live webcast of the presentation at the Barclays 26th Annual Global Healthcare Conference please visit: https://investor.arbutusbio.com/events-presentations .
  • An archived replay of the webcast will be available on the Arbutus website for a limited time after the event.

Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, February 29, 2024
LNP, HBV, Court, PD, Research, Virology, Expert witness, CFBV, AASLD, Construction, Nivolumab, Investment, Arbutus, HBsAg, EASL, Vaccine, Interim, Safety, COVID-19, Pharmacokinetics, Roivant Sciences, Patient, Clinical trial, Congress, RNA interference, DNA, Pharmaceutical industry

Arbutus plans to announce end-of-treatment data from this trial in the first half of 2024.

Key Points: 
  • Arbutus plans to announce end-of-treatment data from this trial in the first half of 2024.
  • Arbutus plans to announce end-of-treatment data from this portion of the trial in the first half of 2024.
  • Arbutus is advancing AB-101 into part two of this clinical trial which involves dosing healthy subjects with multiple-ascending doses of AB-101.
  • Roivant Sciences Ltd. owned approximately 23% of the Company’s outstanding common shares as of December 31, 2023.

Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update

Retrieved on: 
Thursday, February 15, 2024
Arbutus, Virology, CFBV, Conference, Broadcasting

WARMINSTER, Pa., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it has scheduled its fourth quarter and year end 2023 financial results and corporate update for Thursday, February 29, 2024.

Key Points: 
  • WARMINSTER, Pa., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it has scheduled its fourth quarter and year end 2023 financial results and corporate update for Thursday, February 29, 2024.
  • The schedule for the press release and conference call/webcast are as follows:
    Q4 and Year End 2023 Press Release:
    Q4 and Year End 2023 Conference Call/Webcast:
    To dial-in for the conference call by phone, please register using the following link: Registration Link .
  • A live webcast of the conference call can be accessed through the Investors section of Arbutus' website at www.arbutusbio.com .
  • An archived webcast will be available on the Arbutus website after the event.

Arbutus Announces 2024 Corporate Objectives and Provides Financial Update

Retrieved on: 
Monday, January 8, 2024
LNP, RNA interference, AASLD, Virology, HBV, Vaccine, Court, Nivolumab, Congress, Clinical trial, Pharmacokinetics, PD, Expert witness, Arbutus, COVID-19, EASL, CFBV, Interim, Investment, Patient, Safety, HBsAg, PD-L1, Pharmaceutical industry

Arbutus plans to announce end-of-treatment data from this trial in the first half of 2024.

Key Points: 
  • Arbutus plans to announce end-of-treatment data from this trial in the first half of 2024.
  • Arbutus plans to announce end-of-treatment data from this portion of the trial in the first half of 2024.
  • Arbutus expects to report preliminary data from the healthy subject portion of this clinical trial, including target engagement and receptor occupancy data, in the first half of 2024.
  • With respect to the Moderna lawsuit, fact discovery is currently on-going with the claim construction hearing scheduled for February 8, 2024.

Barinthus Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Developments

Retrieved on: 
Thursday, November 9, 2023
Hepatology, Research, Immune system, Depreciation, HBV, Hepatitis B, Arbutus, Vaccine, Liver, Infection, Healing, Cancer, Autoimmunity, Pharmaceutical industry, Vaccitech

OXFORD, United Kingdom, Nov. 09, 2023 (GLOBE NEWSWIRE) --  Barinthus Biotherapeutics plc (NASDAQ: BRNS), formerly Vaccitech plc, today announced its financial results for the third quarter of 2023 and provided an overview of its progress.

Key Points: 
  • OXFORD, United Kingdom, Nov. 09, 2023 (GLOBE NEWSWIRE) --  Barinthus Biotherapeutics plc (NASDAQ: BRNS), formerly Vaccitech plc, today announced its financial results for the third quarter of 2023 and provided an overview of its progress.
  • “The third quarter of 2023 was a period of solid progress for the Company.
  • We have since revealed the evolution of the company identity from Vaccitech to Barinthus Bio.
  • Cash position: As of September 30, 2023, the Company had cash and cash equivalents of $160.3 million, compared to $173.0 million as of June 30, 2023.

Dr. Jinzi J. Wu Presents at the 10th International Workshop on HBV Cure 2023

Retrieved on: 
Thursday, November 9, 2023
Massachusetts General Hospital, Patient, HKEX, Research, PD-L1, Hepatitis B virus, Trial of the century, Harvard Medical School, AIDS, National Institutes of Health, Lim, Johns Hopkins University, Arbutus, Prevalence, Jacob Aligo, Safety, PD-1, University of Milan, CHB, University of Hong Kong, Virus, Phase, Immunotherapy, Risk, HIV/AIDS research, International Workshop on Lung Health, Bangladesh Technical Education Board, GSK, University, Roche, HBsAg, VIR, University of Oxford, Toronto Centre, Liver disease, HBV, Hook effect, Village Vanguard Live Sessions 3, Vaccine, Pharmaceutical industry, Northwestern University, Immunocore

HANGZHOU and SHAOXING, China, Nov. 8, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces that Dr. Jinzi J. Wu, Founder, Chairman and CEO of Ascletis was invited to attend and have a presentation at the 10th International Workshop on HBV Cure 2023 held at Boston, United States.

Key Points: 
  • HANGZHOU and SHAOXING, China, Nov. 8, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces that Dr. Jinzi J. Wu, Founder, Chairman and CEO of Ascletis was invited to attend and have a presentation at the 10th International Workshop on HBV Cure 2023 held at Boston, United States.
  • The interim analysis included 25 patients who completed 24-week treatment (19 patients in ASC22 cohort and 6 patients in placebo cohort).
  • Topline results indicated that in ASC22 cohort, 4 patients (4/19, 21.1%) achieved HBsAg loss at the end of 24-week treatment.
  • "It's a great honor to be invited to the 10th International Workshop on HBV Cure 2023 and share our latest progress in developing the immune checkpoint inhibitor for functional cure of CHB with the global industry.

Arbutus to Present at Jefferies London Healthcare Conference

Retrieved on: 
Wednesday, November 8, 2023
Arbutus, Virology, GMT, Conference, CFBV, Webcast, EDT, Vaccine

WARMINSTER, Pa., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Arbutus management team will participate in and host one-on-one meetings at the following investor conference:

Key Points: 
  • WARMINSTER, Pa., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Arbutus management team will participate in and host one-on-one meetings at the following investor conference:
    Jefferies London Healthcare Conference: Formal presentation on Wednesday, November 15, 2023 at 11:30 am GMT / 6:30 am EDT.
  • To access the live webcast of the presentation please visit: https://investor.arbutusbio.com/events-presentations .
  • An archived replay of the webcast will be available on the Arbutus website for a limited time after the event.

Arbutus Announces CEO, William Collier, to Retire December 31, 2023

Retrieved on: 
Tuesday, November 7, 2023
Knowledge, Therapy, MD, CFBV, RNA interference, Interim, Retirement, Virology, Patient, HBV, Management, Arbutus

WARMINSTER, Pa., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a cure for people with chronic hepatitis B virus (cHBV) infection, today announced that William Collier will retire from his position as the Company’s President and Chief Executive Officer, and as a member of the Board of Directors, at the end of 2023.

Key Points: 
  • Michael J. McElhaugh , Co-founder and Chief Operating Officer of Arbutus, will serve as Interim President and Chief Executive Officer, effective January 1, 2024.
  • “On behalf of the Board of Directors, I want to thank Bill for his leadership and many contributions to Arbutus,” commented Frank Torti, MD, Chairman of the Board of Directors of Arbutus.
  • I extend my deepest gratitude to our entire team, without whom our shared success would not have been possible.
  • I look forward to positioning Arbutus for continued success and creating value for our shareholders.”